Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8042099 | 0.88 | SIGMAR1 (0.53) | SIGMAR1SMN1; SMN2KDM1ACHRM5CHRM3 | |
| SCHEMBL28705809 | 0.81 | CXCR4 (0.52) | SIGMAR1SMN1; SMN2CHRM5CHRM3MEN1 | |
| SCHEMBL27767768 | 0.80 | SMN1; SMN2 (0.47) | SIGMAR1SMN1; SMN2CHRM5CHRM3 | |
| SCHEMBL29317405 | 0.78 | SMN1; SMN2 (0.46) | SIGMAR1SMN1; SMN2CHRM5CHRM3MEN1 | |
| SCHEMBL12605242 | 0.78 | SMN1; SMN2 (0.46) | SIGMAR1SMN1; SMN2CHRM5CHRM3MEN1 | |
| SCHEMBL9059167 | 0.78 | — | — | |
| SCHEMBL2621583 | 0.77 | SMN1; SMN2 (0.49) | SIGMAR1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL22296937 | 0.77 | KDM1A (0.42) | SIGMAR1SMN1; SMN2KDM1ASLC6A4SLC6A3 | |
| SCHEMBL20328701 | 0.75 | SMN1; SMN2 (0.44) | SIGMAR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20329899 | 0.75 | SIGMAR1 (0.42) | SIGMAR1SMN1; SMN2KDM1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884119-B2 | protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | SIGMAR1 3288/4885SMN1; SMN2 4319/4885KDM1A 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.